BRAF and neoplasm: Regardless of these promising survival data, recent evidence shows that approximately 70–80% of patients with metastatic melanoma harboring a BRAF-mutation and treated with CPI or TT will, at some time, show a relapse of the disease in a real-world setting, which requires the re-initiation of anti-tumor treatments [9].